Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
By G. Genovese, A. Kähler, Robert E. Handsaker, J. Lindberg, Samuel A. Rose, S. Bakhoum, K. Chambert, E. Mick, Benjamin M. Neale, Menachem Fromer and 13 more. New England Journal of Medicine, 2014
3,098 citations recorded by the source corpus.
BACKGROUND Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow–biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.)
Subfields: Cancer Research, Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/858ac45705f0729324dd34baa6a212bbc78757de
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- C. Alix‐Panabières
- K. Pantel
- J. Reis-Filho
- K. Walsh
- Trey Ideker
- Benjamin L. Ebert
- Siddhartha Jaiswal
- Wolf Reik
In Genetics
- Andrew E. Teschendorff
- J. Reis-Filho
- Stephan Beck
- Trey Ideker
- Steve Horvath
- Brock C. Christensen
- K. Helin
- Caroline Relton
In Hematology
Citations in the corpus
- Enhanced detection of circulating tumor DNA by fragment size analysis (2018, neutral): “Results of ever-deeper sequencing are also confounded by the likelihood of false-positive results from detection of mutations from noncancerous cells, clonal expansions in normal epithelia, or clonal hematopoiesis of indeterminate potential (CHIP) (13, 18, 19).”
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022, background): “32 Large efforts have been conducted in this fi eld so far, with studies demonstrating high speci fi city and encouraging sensitivity with error-corrected sequencing 116 that may be combined with protein biomarkers, 117 genome-wide fragmentation patterns 118 and methylation-based ctDNA assays.”
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020, neutral): “Consistent with prior literature 13,14,24 , CH mutations were most frequently identified in DNMT3A, TET2 and ASXL1.”
- The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions (2017, methodology): “Alterations in Zeb2 have been identified as miRNA clusters t(8;21) inv(16)”
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. (2015, methodology): “In the absence of any available intervention to prevent progression, surveillance similar towhat is currently recommended for MGUS could be considered.(4,8,69) In the near term, most individuals who will be screened for somatic mutations will be those with hematologic abnormalities that do not meet ”
- Tet2-mediated Clonal Hematopoiesis Accelerates Heart Failure through a Mechanism Involving the IL-1β/NLRP3 Inflammasome (2018, background): “Recent longitudinal studies have reported that detectable clonal hematopoiesis in non-symptomatic individuals is associated with all-cause mortality (6,7,9).”